Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the rationale behind the Phase III MAJIC study (NCT05057494), which is comparing the combination of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.